Two studies published in the latest issue of the journal Cell by University of Pittsburgh researchers uncover how immunotherapies targeting the immune checkpoints PD1 and LAG3 work together to activate immune responses.
2024
Dr Long on Unmet Needs in BRAF-Mutant Melanoma
Georgina V. Long, MBBS, PhD, FRACP, co-medical director, Melanoma Institute Australia (MIA), and chair, Melanoma Medical Oncology and Translational Research, MIA and Royal North Shore Hospital, The University of Sydney, discusses the remaining unmet needs for patients with BRAF-mutant melanoma and how data from the phase 3 NADINA trial (NCT04949113) could help address some of these needs.
Impact of PD-1 and PD-L1 Expression on Overall Survival in Patients With NSCLC and Melanoma
The conventional treatment paradigms for melanoma and non–small cell lung cancer (NSCLC) have historically centered around surgery, radiation, and chemotherapy.
New Studies Show How Immunotherapies Collaborate to Treat Melanoma
New studies have uncovered how immunotherapies targeting the immune checkpoints PD1 and LAG3 work in concert to active immune responses and may improve outcomes in patients with melanoma compared with monotherapies targeting only PD1.